BRIEF published on 10/10/2025 at 18:35, 8 months 10 days ago Publication mensuelle des droits de vote de Theraclion Investissement Droits De Vote Capital Social Euronext Growth Theraclion
PRESS RELEASE published on 10/10/2025 at 18:30, 8 months 10 days ago Inside Information / Other news releases Theraclion provides monthly update on total voting rights and shares. The French MedTech company uses focused ultrasound for non-invasive treatment. CE-marked platform SONOVEIN® targets varicose veins Voting Rights Shares Theraclion SONOVEIN Focused Ultrasound
PRESS RELEASE published on 10/10/2025 at 18:30, 8 months 10 days ago Informations privilégiées / Autres communiqués Communiqué mensuel sur les droits de vote et actions de Theraclion, société française de MedTech. Détails des actions en circulation et droits de vote réels Euronext PEA PME MedTech France Theraclion
BRIEF published on 09/15/2025 at 18:35, 9 months 5 days ago Theraclion Successfully Completes Pivotal Study with 96.8% Occlusion Rate FDA Clinical Trial Theraclion SONOVEIN® Varicose Veins
BRIEF published on 09/15/2025 at 18:35, 9 months 5 days ago Theraclion Réussit son Étude Pivotal avec un Taux d'Occlusion de 96,8 % FDA Essai Clinique Theraclion SONOVEIN® Varices
PRESS RELEASE published on 09/15/2025 at 18:30, 9 months 5 days ago Informations privilégiées / Autres communiqués Theraclion annonce le succès de son étude pivotale américaine FDA avec un taux d'occlusion de 96,8% pour Sonovein®, sa plateforme de traitement des varices par ultrasons focalisés de haute intensité FDA Theraclion SONOVEIN Étude Pivotale Occlusion
PRESS RELEASE published on 09/15/2025 at 18:30, 9 months 5 days ago Inside Information / Other news releases Theraclion announces successful U.S. FDA pivotal study showing 96.8% occlusion rate with Sonovein® for varicose vein treatment. Results support potential U.S. market entry Theraclion SONOVEIN® U.S. FDA Study Varicose Vein Treatment Occlusion Rate
BRIEF published on 07/25/2025 at 18:35, 10 months 26 days ago Theraclion in full expansion in the first half of 2025 Financial Results Clinical Trials Business Expansion Theraclion SONOVEIN
BRIEF published on 07/25/2025 at 18:35, 10 months 26 days ago Theraclion en pleine expansion au premier semestre 2025 Résultats Financiers Essais Cliniques Expansion Commerciale Theraclion SONOVEIN
PRESS RELEASE published on 07/25/2025 at 18:30, 10 months 26 days ago Inside Information / News release on accounts, results Theraclion reports strong growth in S1 2025 with increased revenue and expansion into new markets. Key achievements include 30% rise in consumables sales and completion of pivotal FDA clinical trial follow-up period Revenue Growth Business Expansion Theraclion FDA Clinical Trial S1 2025
Published on 06/20/2026 at 01:00, 17 hours 54 minutes ago Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 18 hours 54 minutes ago Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 14 hours ago Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 1 day 17 hours ago American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 day 17 hours ago Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting
Published on 06/20/2026 at 06:00, 12 hours 54 minutes ago Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 22 hours 37 minutes ago 2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 20:17, 22 hours 37 minutes ago 2CRSi SA: 2CRSi répond point par point au rapport de Grizzly Research et réaffirme la réalité de son activité
Published on 06/19/2026 at 19:01, 23 hours 53 minutes ago Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 19:33, 23 hours 21 minutes ago Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 23 hours 21 minutes ago Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 23 hours 30 minutes ago Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 23 hours 30 minutes ago Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
